Prafulla C. Gokhale

This study shows DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells, reducing ATR inhibitor efficacy, and suggests combining ATR and DNA-PK inhibition could enhance treatment in such cancers.

This paper develops covalent EGFR inhibitors targeting cysteine 775 and 797, showing improved efficacy and resistance delay in osimertinib-resistant models.

The paper shows that selective inhibition of BRD4-BD2 promotes SPOP-mediated degradation of BRD4/BRD4-NUT in NUT carcinoma, leading to better therapeutic outcomes than pan-BET inhibition.

This study shows that inhibiting mSWI/SNF complexes enhances the effectiveness of KRAS inhibitors in lung cancers by reversing epithelial-mesenchymal transition resistance.

This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.

This study identifies pyrvinium pamoate as a potential therapy for Merkel cell carcinoma by targeting Wnt signaling and multiple cancer vulnerabilities.

The paper identifies EIF4A1 as a vulnerability in AML cells and shows that combining Zotatifin with Venetoclax enhances apoptosis and survival in AML models.

This study identifies EZH2 as a dependency in NUT carcinoma, showing that combining EZH2 and BET inhibitors synergistically blocks tumor growth and prolongs survival.